Status:
RECRUITING
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Lead Sponsor:
The University of Queensland
Collaborating Sponsors:
National Health and Medical Research Council, Australia
Applied Health Research Centre
Conditions:
Kidney Failure, Chronic
Hyperphosphatemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcom...
Detailed Description
Hyperphosphataemia is highly prevalent in patients with end-stage kidney disease (ESKD) and associated with increased mortality risk. The Clinical Practice Guidelines suggest lowering elevated phospha...
Eligibility Criteria
Inclusion
- Age ≥45 years, or Age ≥18 years with diabetes,
- ESKD on haemodialysis or peritoneal dialysis, for at least 3 months,
- Currently prescribed at least one phosphate-lowering medication at any dose
- Able to provide informed consent
Exclusion
- Elective kidney transplantation scheduled,
- Concomitant major illness / comorbidity that may result in death in the next 6 months in the view of the treating physician,
- Participation in an interventional study that is likely to affect serum phosphate concentration.
Key Trial Info
Start Date :
December 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
3600 Patients enrolled
Trial Details
Trial ID
NCT03573089
Start Date
December 10 2019
End Date
December 31 2028
Last Update
July 1 2025
Active Locations (115)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Prince Alfred Hosptial
Camperdown, New South Wales, Australia, 2050
2
Nepean Hospital
Kingswood, New South Wales, Australia, 2750
3
St George Hospital
Kogarah, New South Wales, Australia, 2217
4
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia, 2065